Difference between revisions of "Kaye SB, et al. Clin. Cancer Res. (2012) cited as Ref 610 in DOI: 10.1038/s41392-020-0110-5 (Q9873)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: First Author string (P149): Kaye SB, #quickstatements; #temporary_batch_1589996169159)
(‎Created claim: Page(s) (P105): 6509-6518, #quickstatements; #temporary_batch_1590074839150)
 
(6 intermediate revisions by the same user not shown)
Property / DOI Identifier
 +
Property / DOI Identifier: 10.1158/1078-0432.CCR-12-1796 / rank
 +
Normal rank
Property / PubMed ID
 +
Property / PubMed ID: 23032746 / rank
 +
Normal rank
Property / Publication Date
 +
2012
Timestamp+2012-01-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 year
Before0
After0
Property / Publication Date: 2012 / rank
 +
Normal rank
Property / Published In Name String
 +
Clin. Cancer Res.
Property / Published In Name String: Clin. Cancer Res. / rank
 +
Normal rank
Property / Volume
 +
18
Property / Volume: 18 / rank
 +
Normal rank
Property / title
 +
A phase II randomized placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission (English)
Property / title: A phase II randomized placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission (English) / rank
 +
Normal rank
Property / Page(s)
 +
6509-6518
Property / Page(s): 6509-6518 / rank
 +
Normal rank

Latest revision as of 15:46, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Kaye SB, et al. Clin. Cancer Res. (2012) cited as Ref 610 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Kaye SB
    0 references
    0 references
    2012
    0 references
    Clin. Cancer Res.
    0 references
    18
    0 references
    A phase II randomized placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission (English)
    0 references
    6509-6518
    0 references